GlassScriptPhysician profile
Shruti Murali
NPI 1902241649
$4,198.80
in general payments reported to CMS, 2019-2025
39 companies · $1,364 in 2025
The $1,364 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $183 · 2021: $180 · 2022: $19.30 · 2023: $409 · 2024: $1,310 · 2025: $1,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,083.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $379.69 | 2019-2024 | Venclexta, Gazyva |
| Pfizer INC. | $343.68 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $294.82 | 2023-2025 | |
| Glaxosmithkline, LLC. | $279.35 | 2023-2025 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $226.00 | 2019-2024 | Imfinzi, Lynparza, Calquence |
| Exelixis INC. | $186.18 | 2019-2025 | Cabometyx |
| Janssen Biotech, INC. | $160.26 | 2023-2025 | Rybrevant, Talvey, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $156.86 | 2021-2025 | Opdivo, Opdualag |
| Caris Mpi, INC. | $153.44 | 2025 | Mi Cancer Seek |
| Takeda Pharmaceuticals U.S.A., INC. | $138.58 | 2024-2025 | Ninlaro, Vpriv, Fruzaqla |
| Abbvie INC. | $134.82 | 2024-2025 | |
| Incyte Corporation | $128.37 | 2023-2025 | Jakafi, Niktimvo |
| Celgene Corporation | $122.75 | 2024-2025 | Reblozyl, Pomalyst |
| Lilly USA, LLC | $122.22 | 2019-2024 | Verzenio, Jaypirca |
| Intera Oncology, INC | $114.21 | 2024 | Intera |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $113.13 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Pharmacyclics LLC, An Abbvie Company | $109.84 | 2019 | |
| Merck Sharp & Dohme LLC | $106.89 | 2024-2025 | Keytruda, Keytruda Qlex |
| Seagen INC. | $93.61 | 2020-2023 | Tivdak, Tukysa |
| Puma Biotechnology, INC. | $88.61 | 2019-2020 | |
| Mirati Therapeutics, INC. | $86.09 | 2023-2024 | Krazati |
| Regeneron Healthcare Solutions, INC. | $74.57 | 2024 | Libtayo |
| Gilead Sciences, INC. | $74.47 | 2019-2025 | Trodelvy |
| Array Biopharma INC | $73.10 | 2021-2025 | Lorbrena, Braftovi, Mektovi |
| Astellas Pharma US INC | $57.47 | 2024 | Padcev |
| Alexion Pharmaceuticals, INC. | $51.36 | 2024 | Ultomiris |
| Beigene USA, INC. | $48.64 | 2025 | Tevimbra, Brukinsa |
| Stemline Therapeutics INC. | $39.16 | 2025 | Orserdu |
| Pharmaessentia USA Corporation | $31.67 | 2025 | Besremi |
| Eisai INC. | $29.94 | 2025 | |
| Tempus Ai, INC | $29.23 | 2024 | |
| Sobi, INC | $27.58 | 2024 | |
| Coherus Oncology, INC. | $25.62 | 2024 | |
| Spectrum Pharmaceuticals INC. | $22.40 | 2023 | Rolvedon |
| Genzyme Corporation | $22.37 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.10 | 2025 | |
| Acrotech Biopharma INC. | $15.49 | 2024 | Beleodaq |
| Deciphera Pharmaceuticals INC. | $14.23 | 2025 | Qinlock, Tgct |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shruti Murali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.